Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)

Trial Profile

Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms RELAZA2
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Feb 2016 Planned End Date changed from 1 Oct 2017 to 1 Jun 2020 as reported by ClinicalTrials.gov record.
    • 09 Feb 2016 Planned primary completion date changed from 1 Jan 2015 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top